跳至主要内容
临床试验/EUCTR2015-005155-27-HR
EUCTR2015-005155-27-HR进行中(未招募)1 期

Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and paranasal cavity and in patients with acute rhinitis – SeptaNazal DOUBLE clinical study.

KRKA-FARMA d.o.o.0 个研究点目标入组 223 人开始时间: 2016年12月15日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
223

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with acute rhinitis (Group 1):
  • Aged 18-60 years
  • Diagnosed with acute rhinitis
  • Can carry out intranasal administration of the investigational medicinal
  • Signed Informed consent form
  • Patients after nasal surgery or nasal cavities surgery (Group 2):
  • Aged 18-60 years
  • Recent nasal surgery or nasal cavities surgery (patients with chronic
  • rinosinusitis with nasal polyps (CRSwNP) and patients with chronic
  • rinosinusitis without nasal polyps (CRSsNP)
  • Can carry out intranasal administration of the investigational medicinal
  • Signed Informed consent form
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 223
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Hypersensitivity to the active substances or to any of the excipients
  • Dry nasal inflammation (rhinitis sicca)
  • History of transsfenoidal hypophysectomy or other surgical procedures in which the dura mater was exposed
  • Patients who are treated with drugs for local or systemic treatment of influenza, and sympathomimetic agents, which contain a medicament for the treatment for cough and/or cold
  • Pregnancy or breast-feeding
  • Patients with asthma who require treatment with corticosteroids
  • Rhinitis medicamentosa
  • Chronic rhinitis
  • Patients treated with monoamine oxidase inhibitors (MAOIs) or other drugs that may raise blood pressure
  • Patients with increased intraocular pressure, in particular with angle-closure glaucoma
  • Patients with pheochromocytom
  • Nose injury less than 3 months prior the first visit
  • Current treatment with nasal decongestants
  • Respiratory tract infection within 2 weeks prior the first visit (including otitis media), who required treatment with antibiotics
  • Current smoker or ex-smoker less than 6 months prior the first visit
  • Participation in another clinical trial within thirty days prior the first visit

研究者

相似试验